Authors
David J Allsop, Jan Copeland, Nicholas Lintzeris, Adrian J Dunlop, Mark Montebello, Craig Sadler, Gonzalo R Rivas, Rohan M Holland, Peter Muhleisen, Melissa M Norberg, Jessica Booth, Iain S McGregor
Publication date
2014/3/1
Journal
JAMA psychiatry
Volume
71
Issue
3
Pages
281-291
Publisher
American Medical Association
Description
Importance
There are no medications approved for treating cannabis dependence or withdrawal. The cannabis extract nabiximols (Sativex), developed as a multiple sclerosis treatment, offers a potential agonist medication for cannabis withdrawal.
Objective
To evaluate the safety and efficacy of nabiximols in treating cannabis withdrawal.
Design, Setting, and Participants
A 2-site, double-blind randomized clinical inpatient trial with a 28-day follow-up was conducted in New South Wales, Australia. Participants included 51DSM-IV-TRcannabis-dependent treatment seekers.
Interventions
A 6-day regimen of nabiximols (maximum daily dose, 86.4 mg of Δ9-tetrahydrocannabinol and 80 mg of cannabidiol) or placebo with standardized psychosocial interventions during a 9-day admission.
Main Outcomes and Measures
Severity of cannabis withdrawal and cravings (Cannabis Withdrawal Scale), retention in withdrawal …
Scholar articles
Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial
DJ Allsop, J Copeland, N Lintzeris, AJ Dunlop… - JAMA psychiatry, 2014